Novaliq GmbH
Quick facts
Marketed products
- Cyclosporine ophthalmic solution, 0.1% · Ophthalmology
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the eye. - Saline solution, 0.6% · Ophthalmology
Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue.
Phase 3 pipeline
- CyclASol Ophthalmic Solution · Ophthalmology
CyclASol is a cyclosporine A ophthalmic emulsion that suppresses local immune responses in the eye to reduce inflammation and improve tear production in dry eye disease. - CyclASol topical ocular, eye drops · Ophthalmology
CyclASol is a cyclosporine A formulation in a novel aqueous nanomicellar vehicle designed to enhance corneal penetration and treat dry eye disease by suppressing ocular surface inflammation. - Vehicle topical ocular, eye drops · Ophthalmology
Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: